Essure Defective Birth Control Device

Are You Suffering Because of a Defective Essure Birth Control Device?

Doctors implanted Bayer’s Essure® permanent contraceptive device in thousands of women from 2002 to 2016. It was designed to be a non-surgical option for permanent sterilization. Made of metallic coils and polyester fibers, Essure is implanted into a woman’s fallopian tubes. Three months after implantation, the device causes scar tissue to build around the coils, obstructing the fallopian tubes and stopping insemination. Unfortunately, the device migrates, perforates organs, breaks and causes severe reactions and medical conditions, which require surgical removal of the defective device.

CALL US NOW AT 888-585-2188 FOR YOUR FREE CONSULTATION

We only handle cases on a contingency fee basis—we charge no fees or expenses unless there is a recovery in the case.

The Food and Drug Administration (FDA) began examining the rising number of serious problems associated with the use of Essure. In September 2015, the FDA held an Advisory Committee to listen to scientific and medical expert opinions and users’ experiences on the risks and rewards of the device. Following that hearing, in 2016, the FDA required a “black box warning,” additional clinical trials on safety and efficacy, and a multi-page Patient Decision Checklist for physicians to ensure that patients implanted with the device are aware of the true risks associated with the device.

After countless complaints and thousands of injuries, Bayer ultimately withdrew Essure from every country in the world, and announced in July 2018 that it would stop selling the device at the end of 2018.

If you have suffered any health damage due to the use of the Essure permanent birth control system, give us a call at 888-585-2188 for a free consultation. Jenner Law is a leader in the field of medical device litigation and can give you the guidance you need.

ROB JENNER serves on the Essure Plaintiffs’ Steering Committee of the California Judicial Council Coordinated Proceedings in Oakland, California (JCCP 4887). He is also Co-Lead Counsel for the Gilead Tenofovir Cases (JCCP 5043); Liaison Counsel for the Zofran litigation (MDL) in Boston; and Liaison Counsel for the Smith & Nephew BHR hip implant litigation (MDL) in Baltimore.